In the absence of an effective anti-fibrotic treatment for SSc and other fibrotic diseases, the aims of this study were to establish whether inhibiting or removing CCN2 gene expression could provide an avenue for blocking the development of a fibrotic phenotype in the lung. The gene discussed is CCN2; the disease is systemic sclerosis.